1. Home
  2. Directory
  3. California
  4. Stanford
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1497863567

RAMONA L DOYLE M.D.
Prescription History 1497863567
Internal Medicine - Pulmonary Disease in Stanford, CA


Quality Rating: 74.46 out of 100 score

NPI Status: Active since August 28, 2006

Contact Information

300 PASTEUR DR
STANFORD, CA
ZIP 94305
Phone: (650) 498-5710

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for RAMONA L DOYLE M.D., an active Pulmonary Disease specialist practicing in Stanford, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 60 documented patient claims. Among these therapy options, the most frequently utilized medication is Opsumit, which accounts for 18 claims alone.

Medication Index

A
O
T
U
No matching medications currently found on file.

Ambrisentan

Generic Formulation: AmbrisentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply1,077
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,619.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,468.28

State Avg Cost Per Claim

$3,447.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ambrisentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, thereby helping to decrease the blood pressure in the lungs, slow the worsening of symptoms, and improve your ability to exercise.

Opsumit

Generic Formulation: MacitentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 517
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills41.7
Peer Average Days Supply1,242
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222,727.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,373.73

State Avg Cost Per Claim

$11,690.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Macitentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, which helps decrease the blood pressure in the lungs, and reduces the risk of worsening of symptoms and hospital stays due to the disease.

Tyvaso Dpi

Generic Formulation: TreprostinilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.1
Peer Average Days Supply451
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $357,801.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,362.57

State Avg Cost Per Claim

$22,153.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to improve symptoms such as shortness of breath and tiredness. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Uptravi

Generic Formulation: SelexipagSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 418
CA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.8
Peer Average Days Supply1,106
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $342,990.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$24,499.31

State Avg Cost Per Claim

$20,673.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like RAMONA L DOYLE M.D. provides transparency into local medical care patterns within Stanford, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.